ZA844558B - Leucine derivatives - Google Patents

Leucine derivatives

Info

Publication number
ZA844558B
ZA844558B ZA844558A ZA844558A ZA844558B ZA 844558 B ZA844558 B ZA 844558B ZA 844558 A ZA844558 A ZA 844558A ZA 844558 A ZA844558 A ZA 844558A ZA 844558 B ZA844558 B ZA 844558B
Authority
ZA
South Africa
Prior art keywords
image
leucine derivatives
leucine
derivatives
hyperlipaemia
Prior art date
Application number
ZA844558A
Other languages
English (en)
Inventor
Paul Hadvary
Ernst Kupfer
Ernst Karl Weibel
Erich Hochuli
Hans Lengsfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4255488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA844558(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA844558B publication Critical patent/ZA844558B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA844558A 1983-06-22 1984-06-15 Leucine derivatives ZA844558B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH341583 1983-06-22

Publications (1)

Publication Number Publication Date
ZA844558B true ZA844558B (en) 1985-02-27

Family

ID=4255488

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA844558A ZA844558B (en) 1983-06-22 1984-06-15 Leucine derivatives

Country Status (26)

Country Link
US (1) US4598089A (fr)
EP (1) EP0129748B1 (fr)
JP (1) JPS6013777A (fr)
KR (1) KR920002314B1 (fr)
AT (1) ATE30025T1 (fr)
AU (1) AU572851B2 (fr)
BG (1) BG60766B2 (fr)
CA (1) CA1247547A (fr)
DE (2) DE19875045I2 (fr)
DK (1) DK160496C (fr)
ES (1) ES533557A0 (fr)
FI (1) FI78694C (fr)
GR (1) GR82120B (fr)
HU (1) HU193579B (fr)
IE (1) IE57761B1 (fr)
IL (1) IL72122A (fr)
LU (1) LU90302I2 (fr)
LV (1) LV5747B4 (fr)
MC (1) MC1602A1 (fr)
MX (1) MX9203633A (fr)
NL (1) NL980029I2 (fr)
NO (2) NO159941C (fr)
NZ (1) NZ208521A (fr)
PH (1) PH19704A (fr)
PT (1) PT78777B (fr)
ZA (1) ZA844558B (fr)

Families Citing this family (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270837A (fr) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (fr) * 1984-12-21 1994-04-26 Pierre Barbier Procede pour la fabrication d'oxetanones
ZA859574B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Process for the manufacture of oxetanones
JPH0618793Y2 (ja) * 1986-06-13 1994-05-18 パイオニア株式会社 作業台
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5017565A (en) * 1989-04-20 1991-05-21 Lange Iii Louis G Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
MY116591A (en) * 1996-04-26 2004-02-28 Hoffmann La Roche Process for the production of lipstatin and tetrahydrolipstatin
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
DK1017408T3 (da) * 1997-02-05 2005-08-01 Hoffmann La Roche Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
US7344713B1 (en) * 1997-07-07 2008-03-18 Pimentel Julio L Decreased fat absorption with an anti-lipase antibody
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
ES2217797T3 (es) * 1998-08-14 2004-11-01 F. Hoffmann-La Roche Ag Vinileteres heterociclicos contra trastornos neurologicos.
ES2201827T3 (es) 1998-12-23 2004-03-16 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de derivados de acido fibrico para indicaciones cardiovasculares.
DK1140190T3 (da) 1998-12-23 2002-12-23 Searle Llc Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
PT1140185E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com agentes sequestrantes de acido biliar para indicacoes cardiovasculares
WO2000038726A1 (fr) 1998-12-23 2000-07-06 G.D. Searle Llc Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle utilisees dans le cadre de maladies cardio-vasculaires
CZ20012342A3 (cs) 1998-12-23 2001-12-12 G. D. Searle Llc Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny fibrové pro kardiovaskulární indikace
EP1140184B1 (fr) 1998-12-23 2003-06-04 G.D. Searle LLC. Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
ES2185523T3 (es) * 1999-01-29 2003-05-01 Hoffmann La Roche Purificacion de lipstatina.
WO2001005408A1 (fr) * 1999-07-14 2001-01-25 Geltex Pharmaceuticals, Inc. Polymeres fixant la graisse, combines eventuellement avec des inhibiteurs de lipase
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
JP2003528830A (ja) 2000-03-10 2003-09-30 ファルマシア・コーポレーション テトラヒドロベンゾチエピン類の製造方法
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
EP1142572A1 (fr) * 2000-04-04 2001-10-10 Volker Dr. Helmstädter Composés contenant de l'oxetanon destinés au traitement des maladies intestinales
EP1296656B1 (fr) 2000-06-27 2006-08-02 F. Hoffmann-La Roche Ag Procede de preparation de composition
SI1307264T1 (en) 2000-07-28 2005-02-28 F. Hoffmann-La Roche Ag New pharmaceutical composition
EP1307263B1 (fr) 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag Nouvelle application d'inhibiteurs de lipase
PT1311260E (pt) * 2000-08-09 2008-05-02 Hoffmann La Roche Utilização de inibidores de lipase para o tratamento da dispepsia
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ．ホフマン−ラ ロシュ アーゲー インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
MXPA03005915A (es) 2000-12-27 2003-09-10 Hoffmann La Roche Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
US20030091610A1 (en) * 2001-03-19 2003-05-15 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
KR100621287B1 (ko) * 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
DE60232170D1 (de) * 2001-08-30 2009-06-10 Alizyme Therapeutics Ltd Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
WO2003040127A1 (fr) 2001-11-02 2003-05-15 G.D. Searle Llc Composes benzothiepine mono- et di-fluores en tant qu'inhibiteurs du transport d'acides biliaires a co-dependance sodique apicale (asbt) et de reprise de taurocholate
US6844174B2 (en) 2001-12-04 2005-01-18 Biogal Gyogyszergyar Rt. Fermentation process for lipstatin and method of extracting lipstatin from a fermentation broth
IL162323A0 (en) * 2001-12-04 2005-11-20 Biogal Pharmaceutical Co Preparation of orlistat and orlistat crystalline forms
CN1620439A (zh) 2001-12-20 2005-05-25 Osi药物公司 胰脂肪酶抑制剂化合物、其合成方法和应用
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
DE60320529T2 (de) * 2002-02-04 2009-06-10 F. Hoffmann-La Roche Ag Chinolinderivate als npy antagonisten
AU2003210305B2 (en) * 2002-02-28 2006-07-06 F. Hoffmann-La Roche Ag Thiazole derivatives as NPY receptor antagonists
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
AU2003226370A1 (en) * 2002-04-17 2003-11-03 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
DE60330764D1 (de) * 2002-04-26 2010-02-11 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CA2489251A1 (fr) * 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Derives de quinazoline
CA2493712A1 (fr) * 2002-08-07 2004-02-19 F. Hoffmann-La Roche Ag Derives d'aminothiazole pouvant servir d'inhibiteurs de recepteur npy5
KR100645684B1 (ko) * 2002-09-12 2006-11-15 에프. 호프만-라 로슈 아게 당뇨병 치료에 유용한 ｐｐａｒ 작동제로서 ｎ-치환된-1ｈ-인돌-5-프로파이온산 화합물
JP4384052B2 (ja) * 2002-11-25 2009-12-16 エフ．ホフマン−ラ ロシュ アーゲー インドリル誘導体
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
EP1457206A1 (fr) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
WO2004106299A2 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Derives pyrroliques substitues
WO2004113314A1 (fr) * 2003-06-23 2004-12-29 Biocon Limited Nouveaux esters de boronate
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005007639A1 (fr) * 2003-07-17 2005-01-27 Biocon Limited Preparation de tetrahydrolipstatine par hydrogenation de lipstatine, extraction par solvant et purification
ATE380189T1 (de) * 2003-08-12 2007-12-15 Hoffmann La Roche 2-amino-5-benzoylthiazol npy-antagonisten
WO2005014593A1 (fr) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Derives de thiazole utiles comme antagonistes de npy *
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
EP2428516A1 (fr) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (ja) * 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
PL209905B1 (pl) * 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
KR20060124679A (ko) 2004-01-16 2006-12-05 후지 세이유 가부시키가이샤 리파아제 저해제
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
AU2005239788A1 (en) 2004-05-10 2005-11-17 University Of Copenhagen Flaxseeds for body weight management
US7879866B2 (en) * 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
MX2007004889A (es) 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
WO2006110809A2 (fr) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Formulations inhibitrices de lipase nanoparticulaire
ATE514698T1 (de) * 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
WO2006138418A2 (fr) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007018248A1 (fr) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Composé de pyridone
CA2618568A1 (fr) * 2005-08-18 2007-02-22 F. Hoffmann-La Roche Ag Derives de thiazolylpiperidines
WO2007024004A1 (fr) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Dérivé phénylpyridone
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
US7355055B2 (en) * 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
WO2007048027A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Combinaison de composes organiques
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
WO2007055418A1 (fr) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Derive spiro aza-substitue
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2006319232B2 (en) * 2005-11-30 2012-09-13 F. Hoffmann-La Roche Ag 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators
BRPI0619233A2 (pt) * 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
EP1957479B1 (fr) * 2005-11-30 2011-03-02 F. Hoffmann-La Roche AG Derives de indole-2-yl amide substitues en 1,5
ATE448230T1 (de) * 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
JP2009519290A (ja) * 2005-12-15 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー ピロロ［２，３−ｃ］ピリジン誘導体
KR101015666B1 (ko) * 2005-12-16 2011-02-22 에프. 호프만-라 로슈 아게 Ｈ3 수용체 조절제로서 피롤로[2,3-ｂ]피리딘 유도체
SK22006A3 (sk) * 2006-01-03 2007-08-02 Biotika, A. S. Kmeň Streptomyces toxytricini produkujúci lipstatín a príprava lipstatínu s uvedeným kmeňom
US20080021092A1 (en) * 2006-01-06 2008-01-24 Deepak Murpani Stable pharmaceutical compositions of orlistat
WO2007080140A1 (fr) * 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Dérivés de méthanone de type cyclohexyle et pipérazinyle et leur application en tant que modulateurs du récepteur h3 de l'histamine
CA2637449A1 (fr) * 2006-01-23 2007-07-26 F. Hoffmann-La Roche Ag Derives de cyclohexylsulfonamide presentant une activite vis-a-vis des recepteurs h3
WO2008020314A2 (fr) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Formulations de dosage stabilisantes à base de statine
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
JP2009538859A (ja) * 2006-05-30 2009-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペリジニルピリミジン誘導体
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008045564A2 (fr) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Composés de carboxamide et leur utilisation
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2008124120A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines et d'agent anti-obésité
WO2008124122A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines, d'agent anti-obésité et de glitazones
EP2581081A3 (fr) * 2007-06-01 2013-07-31 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008149321A2 (fr) * 2007-06-06 2008-12-11 Ranbaxy Laboratories Limited Procédé perfectionné pour la préparation d'orlistat
US9066536B2 (en) 2007-09-12 2015-06-30 University Of Copenhagen Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20100196464A1 (en) * 2007-09-17 2010-08-05 Dr. Reddy's Laboratories Limited Orlistat pharmaceutical formulations
WO2009044380A2 (fr) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations contenant des particules d'orlistat à dimension de particule contrôlée
EP2219614A1 (fr) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Composition pharmaceutique d'orlistat
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
RU2010128543A (ru) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
ES2755736T3 (es) * 2008-03-26 2020-04-23 Biocon Ltd Proceso de fermentación mejorado para un coeficiente de rendimiento más alto de inhibidor de lipasa respecto al ácido graso consumido
CN101981025A (zh) 2008-03-28 2011-02-23 万有制药株式会社 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2141236A1 (fr) * 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Procédé de production de lipstatine et microorganismes correspondant
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (fr) 2008-07-30 2010-02-04 萬有製薬株式会社 Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons)–(6 chaînons)
CN102170798B (zh) 2008-10-03 2013-06-12 西格马食品可变资本有限公司 用于促进对总胆固醇和ldl胆固醇的控制和/或体重减轻和/或生热作用的组合物
WO2010042499A1 (fr) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Solutions stables d'orlistat pour formes galéniques pharmaceutiques
WO2010043592A1 (fr) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Inhibiteurs de la lipase destinés à être utilisés dans le traitement de l’obésité
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
EP2395987A1 (fr) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
US20100215635A1 (en) * 2009-02-23 2010-08-26 Zoltan Kiss Small molecules to induce weight loss or to reduce weight gain
EP2414830A2 (fr) 2009-03-31 2012-02-08 Robert Zimmermann Modulation de l'adipose triglycéride lipase pour prévenir et traiter la cachexie, la perte de poids et l'atrophie musculaire et procédés de criblage à des fins d'identification
WO2010112569A1 (fr) 2009-03-31 2010-10-07 Robert Zimmermann Modulation de lipase de triglycérides d'adipose pour la prévention et le traitement d'une cachexie, d'une perte de poids et d'une atrophie musculaire et procédés de criblage s'y rapportant
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
ME02016B (me) 2009-11-02 2015-05-20 Pfizer Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
US8524909B2 (en) 2010-02-02 2013-09-03 Hoffmann-La Roche Inc. Tetrahydro-pyran derivatives
CA2786314A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques
WO2011140296A1 (fr) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles utilisés comme inhibiteurs d'acides gras synthase (fasn)
EP2566853B1 (fr) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tétrazolones utilisés en tant qu'inhibiteurs d'acide gras synthase (fasn)
WO2011145022A1 (fr) 2010-05-21 2011-11-24 Pfizer Inc. 2-phénylbenzoylamides
US9237762B2 (en) 2010-05-24 2016-01-19 Swedish Oat Fiber Ab Aqueous dispersion comprising galactolipids and method for production thereof
EP2392327A1 (fr) 2010-06-04 2011-12-07 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Utilisation d'orlistat pour le traitement antiparasite d'une maladie de parasite
EP2590969B1 (fr) 2010-07-06 2014-10-15 AstraZeneca AB Agents thérapeutiques 976
CN101885713B (zh) * 2010-07-19 2011-11-30 大邦(湖南)生物制药有限公司 一种毒三素链霉菌发酵液中分离提取利普司他汀的工艺
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN101948450B (zh) * 2010-10-13 2013-04-24 鲁南制药集团股份有限公司 一种生产制备奥利司他的方法
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
CN103228270B (zh) 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
RU2591188C2 (ru) 2010-11-08 2016-07-10 Альбирео Аб Ингибиторы ibat для лечения заболеваний печени
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
EP2680874A2 (fr) 2011-03-04 2014-01-08 Pfizer Inc Peptides de type edn3 et utilisations associées
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN102304105B (zh) * 2011-07-15 2013-07-10 鲁南新时代生物技术有限公司 一种制备高纯度奥利司他的方法
CN103030613B (zh) * 2011-09-29 2014-11-12 北大方正集团有限公司 一种利普司他汀的提纯方法
JP2013249293A (ja) * 2012-06-04 2013-12-12 Kao Corp リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
WO2014060445A1 (fr) 2012-10-19 2014-04-24 Akzo Nobel Chemicals International B.V. Procédé de préparation d'orlistat à haut degré de pureté
CN102936234B (zh) * 2012-11-15 2015-04-01 江苏阿尔法药业有限公司 一种制备脂肪酶抑制剂奥利司他的方法
CN102993134B (zh) * 2012-12-31 2015-08-05 鲁南新时代生物技术有限公司 一种利普司他汀的提纯方法
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
WO2014170786A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN109310646A (zh) 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
EP4101467A4 (fr) 2020-02-05 2024-03-06 NOF Corporation Agent pour traiter ou prévenir une fistule pancréatique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1328881C (fr) * 1984-12-21 1994-04-26 Pierre Barbier Procede pour la fabrication d'oxetanones

Also Published As

Publication number Publication date
NO159941B (no) 1988-11-14
MC1602A1 (fr) 1985-05-09
LU90302I2 (fr) 1998-12-21
JPH0516426B2 (fr) 1993-03-04
AU2947884A (en) 1985-01-03
BG60766B2 (bg) 1996-02-29
ES8600650A1 (es) 1985-10-16
EP0129748B1 (fr) 1987-09-30
FI842422A (fi) 1984-12-23
HU193579B (en) 1987-10-28
PH19704A (en) 1986-06-16
KR920002314B1 (ko) 1992-03-21
DK308584A (da) 1984-12-23
DK308584D0 (da) 1984-06-22
DE3466538D1 (de) 1987-11-05
FI78694B (fi) 1989-05-31
KR850000530A (ko) 1985-02-27
EP0129748A1 (fr) 1985-01-02
ATE30025T1 (de) 1987-10-15
JPS6013777A (ja) 1985-01-24
NO159941C (no) 1989-02-22
DE19875045I2 (de) 2000-01-20
NL980029I2 (nl) 1999-06-01
LV5747A4 (lv) 1996-10-20
NO2000003I1 (no) 2000-05-31
HUT34545A (en) 1985-03-28
DK160496B (da) 1991-03-18
GR82120B (fr) 1984-12-13
IL72122A0 (en) 1984-10-31
NL980029I1 (nl) 1999-01-04
PT78777B (en) 1986-09-15
DK160496C (da) 1991-08-26
MX9203633A (es) 1992-07-01
NO842512L (no) 1984-12-27
PT78777A (en) 1984-07-01
ES533557A0 (es) 1985-10-16
FI78694C (fi) 1989-09-11
AU572851B2 (en) 1988-05-19
CA1247547A (fr) 1988-12-28
IL72122A (en) 1987-07-31
LV5747B4 (lv) 1996-12-20
NZ208521A (en) 1988-02-29
FI842422A0 (fi) 1984-06-14
US4598089A (en) 1986-07-01
IE841566L (en) 1984-12-22
IE57761B1 (en) 1993-03-24

Similar Documents

Publication Publication Date Title
AU572851B2 (en) Leucine derivatives
AU563466B2 (en) Antibiotic a 51568 factors a and b